Skip to content

Potential New Treatment for Alpha-1 Antitrypsin Deficiency

Search Clinical Trials

Trial Objectives

Researchers want to see if a new drug, alvelestat, improves the symptoms of lung disease caused by COPD due to alpha-1 antitrypsin deficiency (AATD), as well as symptoms of the AATD.


Active Clinical Trials Closed to Recruitment

Who Can Participate

People between the ages of 18-80 with chronic obstructive pulmonary disease (COPD) due to alpha-1 antitrypsin deficiency (AATD) may be eligible to participate.

Age: 18-80 Gender: Any

Estimated Time Commitment

Not Specified

Payment & Reimbursement

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Kristina Eliopoulos

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

National Institutes of Health, University of Alabama at Birmingham

Principal Investigators

Robert A. Sandhaus

Robert A. Sandhaus, MD, PhD, FCCP

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.